Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
#f |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
8/13/26 21:52 | 8/5/26 | ATTO | Health | BioPrd | Biological Products, (No Diag | Walsh Colin | NY | D | 1 | P.dm | 10,285 | 17.58 | 0 | 585 | 24 | 3,021 | I | |||||||||||||||
8/13/26 21:51 | 8/5/26 | ATTO | Financ | FinTrd | Security Brokers, Dealers & F | Goldman Sachs Group Inc | NY | H | Former 1 | 1 | P.dm | 10,285 | 17.58 | 0 | 585 | 24 | 3,021 | I | ||||||||||||||
8/10/26 16:12 | 8/6/26 | ATTO | Health | BioPrd | Biological Products, (No Diag | Venbio Global Strategic Fund Iv, L.P. | CA | T | 1 | P.d | 6,500 | 17.00 | 0 | 382 | 10 | 4,181 | D | |||||||||||||||
8/7/26 21:47 | 8/6/26 | ATTO | Health | BioPrd | Biological Products, (No Diag | Redmile Group, LLC | CA | T | 1 | P.d | 10,200 | 17.00 | 0 | 600 | 38 | 2,166 | M | |||||||||||||||
8/7/26 15:45 | 8/6/26 | ATTO | Health | Drug | Pharmaceutical Preparations | Sanofi | T | 1 | P.d | 5,100 | 17.00 | 0 | 300 | 38 | 1,083 | I | ||||||||||||||||
8/6/26 17:35 | 8/6/26 | ATTO | Health | BioPrd | Biological Products, (No Diag | Frazier Life Sciences Xi, L.P. | CA | T | 1 | P.d | 10,000 | 17.00 | 0 | 588 | 11 | 6,154 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |